Phase 1 bioequivalence study of dapagliflozin/sitagliptin FDC vs loose combination of single components

Trial Identifier:	D1683C00014
Sponsor:	AstraZeneca
Collaborator:	Parexel
NCTID::	NCT05266404
Start Date:	March 2022
Primary Completion Date:	May 2022
Study Completion Date:	May 2022

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description
	English Version
	German Translation

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
DE	Berlin, DE, 14050

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.